absent | present | total | |
disease + | 17 | 25 | 42 |
no disease - | 202 | 6 | 208 |
total | 219 | 31 | 250 |
a) P(false positve rate) = 17/250 =
0.068
b) P(false negative) = 6/250=
0.024
c)to be independent events
P(has disease and disease not detected) = P(has disease)*P(disease
not detected)
P(has disease and disease not detected) = 6/250
0.024
P(has disease)*P(disease not detected) =
31/250*208/250=
0.103168
since, P(has disease and disease not detected) ╪ P(has
disease)*P(disease not detected)
so, events are not indepdnet
d) events to be mutually exclusive, P(A and B) must be
0
but here, P(has disease and disease not detected) ╪0
so, events are not mutually exclusive
2. A study was conducted to investigate a new procedure for detecting renal disease in patients...
In a study of 380 diabetics and nondiabetics, patients were classified as underweight, normal weight, overweight and obese according to their diabetes status. The probability of being normal weight is 0.31 and the probability of having diabetes is 0.39. If you select two individuals from the population, the probability of being diabetic and normal weight is 0.09. What is the probability that either of the two randomly selected individuals (or both) will be diabetic or normal weight? a. Pr (diabetic...
Case Study Coronary Heart Disease Assignment: 16 points Resources needed to completed assignment: 1. Lewis Text Book 2. Nurses Drug Guide 3. Core Concepts of Pharmacology 5thedition SITE YOUR RESOURCES AFTER EACH QUESTION. May work in groups. Scenario: You are a nurse at a freestanding cardiac prevention and rehabilitation center. Your new patient in risk-factor modification is B.T., a 41-year-old old traveling salesman, who is married and has three children. He tells you that his work does not let him slow down....
Identify the scientific premise, main hypothesis addressed by the paper and the research question of the paper Also, what is the main results and the implication of results IMPORTANCE Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been reported. OBJECTIVE To determine whether single-agent PD-1 blockade with nivolumab...